Eric Kelts, MD
Neurology · Centennial, CONPI 1861541005
Payments from drug & device makers
Across 130 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$422
- AstraZeneca$297
- Biogen$284
- Novartis$258
- Pfizer$157
- EMD Serono, Inc.$139
- plus $1K from 27 others
What the payments were for
- Consulting fees$1505%
- Speaking & faculty fees$763%
- Food & beverage$2,77892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $422 |
| AstraZeneca | 8 | $297 |
| Biogen | 10 | $284 |
| Novartis | 14 | $258 |
| Pfizer | 9 | $157 |
| EMD Serono, Inc. | 1 | $139 |
| Genentech USA, Inc. | 7 | $133 |
| TG Therapeutics, Inc. | 1 | $128 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Amgen | 8 | $124 |
| Amneal Pharmaceuticals LLC | 6 | $113 |
| UCB, Inc. | 6 | $110 |
| Bristol Myers Squibb | 6 | $96 |
| Teva Pharmaceuticals USA, Inc. | 6 | $89 |
| Acorda Therapeutics, Inc | 4 | $76 |
| CSL Behring | 2 | $48 |
| Livanova USA, Inc. | 3 | $48 |
| Acadia Pharmaceuticals Inc | 3 | $45 |
| Harmony Biosciences LLC | 2 | $39 |
| Sanofi | 2 | $35 |
| Kyowa Kirin, Inc. | 2 | $29 |
| SK Life Science, Inc. | 2 | $28 |
| Argenx US, Inc. | 1 | $28 |
| GRT US Holding, Inc. | 1 | $19 |
| Aquestive Therapeutics, Inc. | 1 | $18 |
| Greenwich Biosciences, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Zogenix Inc. | 1 | $13 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,003 in reported general payments places this provider in the 55th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rebif RebidoseInterferon Beta-1a/Albumin | 13 | $134,950 |
| AustedoDeutetrabenazine | 12 | $129,674 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $108,003 |
| TecfideraDimethyl Fumarate | 12 | $105,552 |
| Dimethyl Fumarate | 12 | $53,928 |
| Dalfampridine ErDalfampridine | 33 | $16,023 |
| QuliptaAtogepant | 12 | $12,433 |
| Emgality PenGalcanezumab-Gnlm | 14 | $11,483 |
| Acetazolamide | 53 | $4,083 |
| Mycophenolate Mofetil | 24 | $2,333 |
| Gabapentin | 223 | $2,095 |
| Pyridostigmine Bromide | 12 | $1,376 |
| Memantine Hcl | 109 | $1,356 |
| Carbamazepine ErCarbamazepine | 18 | $1,300 |
| Pregabalin | 70 | $1,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Tecfidera | $284 | $213,55525 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Acyclovir | $89 | $129,75329 claims |
| AbbVieQulipta | $422 | $12,43312 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $113 | $3,70936 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $57252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 334 neurology providers in Colorado.
Other neurology in Centennial
- Ronald MurrayCentennial$1.3M
- Enrique AlvarezAurora$14.3M
- Rajeev KumarEnglewood$14.3M
- Tamara MillerFort Collins$7.4M
- Alison AllenBasalt$4.6M
- Adam WolffDenver$2.4M
- Kimberly WagnerColorado Springs$2.3M
- Timothy VollmerAurora$2M
- Jeffrey BennettAurora$1.9M
- William WagnerLouisville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.